Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Phase I Study of LBH589 & Erlotinib for Advanced Aerodigestive Tract Cancers

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Genentech, Inc.
Novartis
Information provided by (Responsible Party):
H. Lee Moffitt Cancer Center and Research Institute
ClinicalTrials.gov Identifier:
NCT00738751
First received: August 18, 2008
Last updated: September 2, 2014
Last verified: August 2014

August 18, 2008
September 2, 2014
November 2008
August 2013   (final data collection date for primary outcome measure)
Maximum Tolerated Dose (MTD) [ Time Frame: 4 Months ] [ Designated as safety issue: Yes ]
Determine safety and tolerability of erlotinib and LBH589B and establish a recommended phase II expansion dosing of LBH589B and erlotinib in patients with advanced aerodigestive tract cancers.
Determine safety and tolerability of erlotinib and LBH589B and establish a recommended phase II expansion dosing of LBH589B and erlotinib in patients with advanced aerodigestive tract cancers. [ Time Frame: Dependent upon results ] [ Designated as safety issue: Yes ]
Complete list of historical versions of study NCT00738751 on ClinicalTrials.gov Archive Site
  • Disease Control Rate (DCR) [ Time Frame: Up to 48 months ] [ Designated as safety issue: No ]
    DCR: The percentage of patients with advanced or metastatic cancer who have achieved complete response (CR), partial response (PR) and stable disease (SD) to a therapeutic intervention in clinical trials of anticancer agents. CR: is defined as disappearance of all target lesions. PR: is defined as at least a 30% decrease in the sum of longest diameter (LD) of target lesions taking as reference the baseline sum LD. SD: is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as references the smallest sum LD since the treatment started.
  • Progression Free Survival (PFS) by Cancer Type [ Time Frame: Up to 48 months ] [ Designated as safety issue: No ]
    Progressive Disease (PD) is defined as at least a 20% increase in the sum of LD of target lesions taking as references the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.
  • Overall Survival (OS) by Cancer Type [ Time Frame: Up to 48 months ] [ Designated as safety issue: No ]
    Overall survival (OS) is the duration from date of randomization to date of death from any cause.
Evaluate safety of erlotinib/LBH589B, pharmacokinetic drug levels of Erlotinib, full profile of single agent vs. combination; biomarkers of acetylation; objective response rate; 6-mo. progression free survival rate; time-to-event variables. [ Time Frame: Dependent upon results ] [ Designated as safety issue: Yes ]
Not Provided
Not Provided
 
Phase I Study of LBH589 & Erlotinib for Advanced Aerodigestive Tract Cancers
Phase I Study of LBH589 in Combination With Erlotinib for Advanced Aerodigestive Tract Cancers (CLBH5889CUS11T)

The main purpose of the study is to:

  • Determine the safety and tolerability of erlotinib and LBH589B.
  • Establish a recommended phase II expansion dosing of LBH589B and erlotinib in patients with advanced aerodigestive tract cancers.
Not Provided
Interventional
Phase 1
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Lung Cancer
  • Head and Neck Cancer
  • Drug: Panobinostat (LBH589)
    Panobinostat was taken twice weekly, for 2 out of 3 weeks of each cycle. Each cycle was defined as a 21-day period. Four dose levels of panobinostat in combination with erlotinib were planned: 1) dose level 1 (DL1) = panobinostat 20 mg by mouth (PO) twice weekly for 2 out of 3 weeks + erlotinib 100 mg PO daily; 2) dose level 2 (DL2) = panobinostat 30 mg and erlotinib 100 mg; 3) dose level 3 (DL3) = panobinostat 30 mg and erlotinib 150 mg; and 4) dose level 4 (DL4) = panobinostat 40 mg and erlotinib 150 mg. Doses were not escalated over the course of treatment of an individual participant.
    Other Names:
    • histone deacetylase inhibitor
    • HDAC
  • Drug: erlotinib
    Erlotinib was taken daily without interruption. Each cycle was defined as a 21-day period. Panobinostat was taken twice weekly, for 2 out of 3 weeks of each cycle. Four dose levels of panobinostat in combination with erlotinib were planned: 1) dose level 1 (DL1) = panobinostat 20 mg by mouth (PO) twice weekly for 2 out of 3 weeks + erlotinib 100 mg PO daily; 2) dose level 2 (DL2) = panobinostat 30 mg and erlotinib 100 mg; 3) dose level 3 (DL3) = panobinostat 30 mg and erlotinib 150 mg; and 4) dose level 4 (DL4) = panobinostat 40 mg and erlotinib 150 mg. Doses were not escalated over the course of treatment of an individual participant.
    Other Names:
    • Tarceva
    • quinazoline
Experimental: Dose Escalation Followed by Expansion
Eligible participants were enrolled in a 3+3 dose-escalation design to determine the maximum tolerated dose (MTD) of twice weekly panobinostat plus daily erlotinib at 4 planned dose levels (DLs).
Interventions:
  • Drug: Panobinostat (LBH589)
  • Drug: erlotinib
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
44
May 2015
August 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Histologically or cytologically documented diagnosis of advanced/metastatic NSCLC or Head and Neck cancer.
  • Male or female patients aged ≥ 18 years old
  • Ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed
  • Have progressive and measurable disease that can be measured by Response Evaluation Criteria in Solid Tumors (RECIST) criteria
  • Patients must have discontinued prior systemic chemotherapy by 14 days.
  • Patients must meet the following laboratory criteria:

    1. Serum albumin ≥ 3g/dL
    2. Aspartic transaminase (AST/SGOT) and alanine transaminase (ALT/SGPT) ≤ 2.5 x upper limit of normal (ULN)or ≤ 5.0 x ULN if the transaminase elevation is due to leukemic involvement
    3. Serum bilirubin ≤ 1.5 x ULN
    4. Serum creatinine ≤ 1.5 x ULN or 24-hour creatinine clearance ≥ 50 ml/min
    5. Serum potassium ≥ lower limit of normal (LLN) and ≤ ULN
    6. Serum phosphorous ≥ LLN
    7. Serum total calcium (corrected for serum albumin) or serum ionized calcium ≥ LLN
    8. Serum magnesium ≥ LLN
    9. Absolute neutrophil count (ANC) (ANC: segmented and bands) ≥ 1.5 X10^9/L
    10. Platelets ≥ 100 X 10^9/L
  • Baseline multiple gated acquisition imaging (MUGA) or echocardiogram (ECHO) must demonstrate left ventricular ejection fraction (LVEF) ≥ the lower limit of the institutional normal
  • Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 1
  • Reproductive potential must be either terminated (by surgery, radiation, or menopause) or attenuated by the use of an approved contraceptive method during and for 3 to 6 months following the study.
  • Patient instructed that intravenous (IV) bisphosphonates will be withheld for the first 8 weeks of LBH589 therapy due to risk of hypocalcemia.

Exclusion Criteria:

  • Impaired cardiac function including any one of the following:

    1. Screening electrocardiogram (ECG) with a corrected QT (QTc) > 450 msec confirmed by central laboratory prior to enrollment to the study
    2. Patients with congenital long QT syndrome
    3. History of sustained ventricular tachycardia
    4. Any history of ventricular fibrillation or torsades de pointes
    5. Bradycardia defined as heart rate < 50 beats per minute. Patients with a pacemaker and heart rate ≥ 50 beats per minute are eligible.
    6. Patients with a myocardial infarction or unstable angina within 6 months of study entry
    7. Congestive heart failure - New York Heart Association (NYHA) class III or IV
    8. Right bundle branch block and left anterior hemiblock (bifascicular block)
    9. Patients with a history of uncontrolled or chronic atrial fibrillation.
  • Uncontrolled hypertension, blood pressure (BP) >180/110 on 3 separate occasions despite oral antihypertensive medications
  • Concomitant use of drugs with a risk of causing torsades de pointes Concomitant use of CYP3A4 inhibitors
  • Patients with documented central nervous system or leptomeningeal metastasis (brain metastasis) at the time of study entry. Patients with prior brain metastasis may be considered if they have completed their treatment for brain metastasis, no longer require corticosteroids, and are asymptomatic.
  • Patients with unresolved diarrhea > Common Terminology Criteria for Adverse Events (CTCAE) grade 1
  • Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral LBH589
  • Other concurrent severe and/or uncontrolled medical conditions
  • Patients who have received chemotherapy < 14 days, any investigational drug < 14 days or undergone major surgery < 4 weeks prior to starting study drug or who have not recovered from side effects of such therapy.
  • Concomitant use of any anti-cancer therapy (except erlotinib) or radiation therapy.
  • Female patients who are pregnant or breast feeding or patients of reproductive potential not using two effective methods of birth control. Women of childbearing potential (WOCBP) must have a negative serum pregnancy test within 7 days of the first administration of oral LBH589
  • Male patients whose sexual partners are WOCBP not using effective birth control
  • Patients with known positivity for human immunodeficiency virus (HIV) or hepatitis C; baseline testing for HIV and hepatitis C is not required
  • Patients with any significant history of non-compliance to medical regimens or with inability to grant a reliable informed consent
  • Patients who are not willing to refrain from wearing contact lenses during study participation will be excluded.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00738751
MCC-15461, LBH589
No
H. Lee Moffitt Cancer Center and Research Institute
H. Lee Moffitt Cancer Center and Research Institute
  • Genentech, Inc.
  • Novartis
Principal Investigator: Jhanelle Gray, M.D. H. Lee Moffitt Cancer Center and Research Institute
H. Lee Moffitt Cancer Center and Research Institute
August 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP